Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...

Failed to fetch dynamically imported module: https://ca.finance.yahoo.com/assets/_app/immutable/nodes/163.BZrKoyEC.js ...

Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by stock analysts at Wells Fargo & Company from $190.00 ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...

We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...

Multiple Sclerosis companies are Immune Response BioPharma, Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., ...

Long-term Tecfidera use was found to significantly reduce relapse rates and slow disability progression for MS patients in a ...

There has also been a shift in treatment preferences over the years in MS towards B-cell depleting therapies like Roche's (OTCQX:RHHBY) Ocrevus (Biogen earned $346.8 million in Q3 from Ocrvus ...